Low-dose, weekly methotrexate is now standard second-line therapy for rheumatoid arthritis.
Methotrexate is the single agent to which new agents or combinations of agents have been
compared in efficacy studies, and methotrexate is included in effective multiple-drug
regimens as well (see other articles elsewhere in this issue). Despite a general expectation
that methotrexate-induced toxicity would be common and severe, most patients tolerate the
drug quite well. Because methotrexate was empirically reintroduced for the treatment of …